CHICAGO, June 05, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society ...

“Summer is the perfect time to embrace crisp, sessionable brews with bright flavors,” said Prinz Pinakatt, Chief Growth ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash. Xilio may elect to cancel unexercised Se ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an ...

Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika ...

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 33,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on June 1, 2026, 2027 and 2028.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to ...

The fireside chat session is scheduled for Monday, June 9, in Miami, FL, at 9:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors ...

Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at I.E. Weldon Secondary School in Lindsay to mark the milestone of more than 25,000 Haliburton – ...

All securities issued pursuant to the Shares-for-Debt Settlement will also be subject to resale restrictions in Canada for a period of 4 months and a day from their date of issuance.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, ...

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal amount of its 8.375% Junior ...